


Americans Support Increased Access to Biosimilars

Biosimilar medicines offer an opportunity to provide greater access to more affordable healthcare treatment options.

Americans overwhelmingly support biosimilar medicines becoming more widely available to patients in the United States



All Americans

And **3 in 4** Americans ages 65+ support wider access, indicating the importance of biosimilar medicines to Medicare

Majorities predict biosimilars will lead to a myriad of better health outcomes for patients

Share of adults who say each of the following are likely if biosimilars are more widely available:

7 in 10


Say patients will be better able to access life-saving prescription drugs

6 in 10


Say increased competition will cause the cost of drugs to decrease

That's why bipartisan majorities agree: Government should promote policies that make biosimilar medicines more accessible to patients


Total support by party:




All Americans



Democrats



Republicans



Independents

What does the FDA say about biosimilars?

Biosimilars are safe and effective options for patients

Biosimilars are approved after rigorous evaluation

Meet FDA's rigorous standards for approval

Are manufactured in FDA-licensed facilities

Are tracked as part of post-market surveillance to ensure continued safety


How is Mylan leading the way on biosimilars?

Mylan has one of the most comprehensive biosimilar portfolios in the pharmaceutical industry:

1 FDA-approved biosimilar product and multiple ex-US approvals

20 biosimilar and insulin products in the global pipeline

Mylan's portfolio covers many of the top biologic medicines most used by patients in the areas of:



Mylan's investments in research and development are investments towards access to biosimilars and other medicines:

\$3B in R&D between 2013-2017

2 global R&D centers

10 technology-focused development sites

3,000+ scientific affairs team members

24/7 Mylan's R&D never stops